Ditch Labs Inc. Appoints Peter Bloch as Chairman of the Board of Directors
MONTREAL, QC, February 11, 2025 — Ditch Labs Inc., a pioneering life sciences company dedicated to revolutionizing nicotine addiction treatment through innovative solutions like the DitchPen®, is proud to announce the appointment of Peter Bloch as Chairman of the Board of Directors. With his extensive experience in both medical devices and therapeutics, Peter Bloch brings a wealth of expertise to guide Ditch Labs as it prepares to achieve major value-creating milestones, including a pivotal comparative bioavailability study unlocking commercialization in the United Kingdom in 2026, and upcoming clinical trials in the United States.
Peter Bloch is a seasoned executive with a remarkable career in the life sciences and medical technology sectors. Notably, as Chief Executive Officer and Chairman at Bionik Labs he led the company from an incubator to a US listed company with sales on four continents.. He has an extensive track record of leading and scaling MedTech and Biotech companies, securing over $100 million in funding through venture capital, IPOs, and strategic partnerships. He has successfully guided multiple companies from concept to commercialization and exit, leveraging his expertise in global growth, revenue expansion, and profitability.
“Ditch Labs is at a turning point, with clinical trials underway and commercialization on the horizon,” said Laurent Laferriere, Co-Founder and CEO of Ditch Labs. “Our device and mobile app are ready, and we are eager to enter significant markets. Peter’s leadership and deep expertise in scaling MedTech companies will be invaluable as we navigate this next phase. His strategic insight will help ensure we successfully navigate the complexities of bringing a medically approved, safe, and effective solution to the millions of smokers and vapers seeking a better way to quit.”
As Chairman of the Board, Mr. Bloch will work closely with Ditch Labs’ executive team to advance its strategic objectives, oversee governance, and strengthen its position as a leader in the nicotine cessation market.
“I am excited to join Ditch Labs and contribute to a product that has the potential to impact the lives of over a billion people worldwide,” said Peter Bloch. “Rarely do we have the chance to make such a profound impact in healthcare, and I look forward to working with the team to deliver meaningful change for individuals struggling with smoking or vaping addiction globally.”
Ditch Labs continues to innovate at the intersection of health and technology, with its flagship product, the DitchPen®, leveraging precise dosing and automated reduction to provide a personalized and gradual cessation experience. With Peter Bloch at the helm of its Board of Directors, the company is determined to advance its vision of a healthier, nicotine-free future.
About Ditch Labs Inc.:
Ditch Labs is a Montreal-based life sciences company developing innovative solutions for smoking and vaping cessation. Its flagship product, the DitchPen®, combines medical-grade nicotine replacement therapy with a user-friendly digital app to deliver a personalized, automated cessation program. Founded by a team of entrepreneurs and healthcare professionals, Ditch Labs is committed to empowering individuals to take control of their health and live nicotine-free lives.